Pfizer Inc/stats, details

Lines of business
Human Healthcare (prescription drug products)

Animal Healthcare

Units/subsidiaries

 * Embrex
 * Warner-Lambert
 * Parke-Davis
 * Animal Health Group
 * Pfizer Austria
 * Pfizer Canada
 * Pfizer Denmark
 * Pfizer Europe
 * Pfizer Global Research and Development
 * Pfizer Ireland
 * Pfizer Italy
 * Pfizer Japan
 * Pfizer Malaysia - Singapore
 * Pfizer Pharmaceuticals Group
 * Pfizer Spain
 * Pfizer Sweden
 * Pfizer Taiwan
 * Pfizer Turkey

Major Acquisitions
Warner-Lambert, February 2000

Pharmacia Corporation, April 2003

Esperion Therapeutics, February 2004

Vicuron Pharmaceutical, September 2005

Major Products By Patent Expiration Date
Zithromaxin(2005) Zoloft(2006) Norvasc (2007) Zyrtec (2007) Camptosar (2008) Aricept (2010) Lipitor (2010) Viagra (2012) Celebrex (2014) Lyrica (2018) Sutent (2021)

Wholesalers
2006: Percent of Total Revenue
 * 1) McKesson Inc 20%
 * 2) Cardinal Health Inc 13%
 * 3) AmerisourcesBergen Corp 11%

Competitors
Merck Sanofi-Aventis GlaxoSmithKline Bristol-Myers Squibb

Countries of operation
Research and Development:
 * USA
 * China
 * England
 * France
 * Japan

Veterinary Medicine Research:
 * Australia

Global Manufacturing:
 * USA
 * Brazil
 * Belgium
 * Germany
 * Ireland
 * Italy
 * Mexico
 * Puerto Rico
 * Singapore
 * Sweden
 * United Kingdom

Breakdown of revenues
2006: By Division
 * 93.2% Pharmaceutical Division
 * 4.8% Animal Health

By Geography
 * US Sales: 53.4% ($25.8 billion)
 * International Sales: 46.6% ($22.5 billion)
 * Japan: 6.7%(of total revenue)

By Major Product:
 * 1) Lipitor $12.9 billion
 * 2) Norvasc $4.87 billion
 * 3) Zoloft $2.1 billion
 * 4) Celebrex $2.04 billiion

2005:
 * 93.4% Pharmaceutical Division ($45 billion)
 * 4.6% Animal Health

Board members & affiliations
Jeffrey B. Kindler, Chairman of the Board Alan G Levin, Chief Financial Officer Loretta Cangialosi, Chief Accounting Officer Dennis Ausiello Michael S. Brown M. Anthoy Burns Robert N. Burt W. Don Cornwell William H. Gray III Constance J. Horner William R. Howell Stanley O. Ikenberry George A. Lorch Henry A. McKinnell, former CEO, Pfizer (2001-2006) Dana G. Mead Ruth J. Simmons Wiliam C. Steere, Jr., former CEO of Pfizer (1991-2001)
 * Former Congressman, Pennsylvania 2nd (1979-1991)
 * Director of Dell
 * Director of Prudecntial
 * Director of JP Morgan Chase
 * Former Civil Rights Commissioner
 * Former CEO, JC Penney (1983-1997)
 * Director TIAA-CREF
 * Former President, American Council on Education (1996-2001)
 * Former President, University of Illinois (1979-1995)
 * CEO of Armstrong
 * Chairman of PhRMA
 * Director of Stanford Graduate School of Business Advisory Council
 * Member Board of Trustees of NYC Public Library
 * Member of the Executive Compensation Committee
 * retired CEO of Tenneco, Inc.
 * Chairman, MIT Corporation
 * President, Brown University
 * Former President of Smith College
 * Director of Metropolitan Life
 * Director of Goldman Sachs Group
 * Director of Texas Instruments
 * Director of Connecticut Mutal Life Insurance
 * Director of Texaco

Executive/director compensation
2006:
 * 1) Henry A. McKinnell: $12,968,829

Labor
98,000 worldwide
 * 38,000 sales representatives
 * 12,000 medical researchers
 * Plan to eliminate 10,000 employees by end of 2008
 * Includes a 20% reduction in European sales force
 * Closing of manufacturing plants in Brooklyn, NY and Omaha, NB.
 * Close research site in Michigan, Japan, and France

HQ Contact information
235 E. 42nd St. New York, NY 10017 Phone: 212-573-2323 Fax: 212-573-7851 Web: http://www.pfizer.com

Country of incorporation
United States (Delaware)

Ownership status
Public

Primary industry sector

 * Pharmaceuticals
 * Animal Health

2007 Primary Industry Ranking
Fortune 500 Rank: 39 (2006, 31)

Fortune Pharmaceutical Industry Rank: 2

Forbes 2000 Profit Rank: 7

Financial Times Global 500: 17

Number of employees worldwide
98,000

Chief executive officer
Jeffrey B. Kindler, 51

Ticker symbol
PFE

Main exchanges
NYSE

Investor website
http://www.pfizer.com/investors

List of largest shareholders

 * Barclays Global Investors, 5.13%
 * AXA, 3.21%
 * State Street Corporation, 3.14%
 * Vanguard Group, 2.94%
 * Capital Research and Management, 2.14%

Total revenue
2006 Net Sales: $48,370,000,000

Net income
2006 Net Income: $19,337,000,000

Books on company

 * Kanter, RM (ed). “Innovation: Breakthrough Thinking at 3M, DuPont, GE, Pfizer and Rubbermaid”, 1997.
 * McKinnell, Hank. “A Call to Action”, 2005.
 * Mines, S. “Pfizer: An Informal History”, 1978.
 * Pratt, Edmund T. “Pfizer: Bringing Science to Life”, 1985.
 * Reidy, Jamie. “Hard Sell: The Evolution of a Viagra Salesman”, 2005.
 * Rodengen, Jeffrey. “The Legend of Pfizer”, 1999.

External resources
Google Newsfeed on Pfizer Pfizer OSHA Report AFL-CIO Executive Paywatch Oxfam Report on Pfizer http://en.wikipedia.org/wiki/Pfizer